Four independent directors elected at the Annual and Special Meeting of Shareholders, September 25, 2025. All directors are independent within the meaning of applicable Canadian and US securities regulations.
John brings 35 years of specialty pharmaceutical, medical device, and commercialisation experience spanning start-up to large pharmaceutical and biotech companies. He served as Group Vice-President and Head of Ophthalmology Franchise for Shire/Takeda, and as Chief Commercial Officer of Oyster Point Pharma. He is currently an Independent Director and Board Member of Alimera Sciences and Cytophage Technologies Ltd. John holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University.
Eric has been a Chartered Professional Accountant since 1986. He held senior accounting and finance positions in industry from 1991, including executive roles within the dairy processing and manufacturing sectors, and has been an active investor in the junior mining market since 1992. His most recent work involved strategic planning and business unit leadership. He has served on several industry-related boards. Eric served as Board Chair prior to the September 2025 AGM.
Matt is a Partner and Project Manager at Catalyst Custom Modular Ltd. in British Columbia, specialising in innovative prefabricated module construction using modern building science. He has commissioned next-generation HVAC systems on both site-built and modular custom homes. Prior to Catalyst, he was the proprietor of Fontes Homes. Matt brings expertise in entrepreneurship, building innovation, and project planning: including direct experience with HVAC filtration systems relevant to Zentek's ZenGUARD platform.
Pete served as Director of International Development at RSK Environment Limited, a global leader in the delivery of environmental and engineering solutions, from 2019 to 2025. Prior to that role, he was Regional Development Director. Middle East at RSK, and Land Manager at Vattenfall in Edinburgh and London. Pete brings expertise in environmental solutions, international business development, and renewable energy: directly relevant to Zentek's government engagement and international market strategy.
All four directors are independent within the meaning of applicable Canadian and US securities regulations. The Board operates three committees: Audit & Governance (Chair: Eric Wallman), Corporate Governance, Compensation & Nominating (Chair: John Snisarenko). Zentek is a foreign private issuer listed on the TSX Venture Exchange (ZEN) and Nasdaq Capital Market (ZTEK). Continuous disclosure documents are filed on SEDAR+ and EDGAR.